Generex Oncology Names Dr. Craig Eagle to its Scientific Advisory Board to Assist with its Proprietary Cancer Vaccines Program

WORCESTER, Mass., Aug. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) (www.generex.com) announced today that it has named Craig Eagle, M.D. to its scientific advisory board.  Dr. Eagle brings a wealth of oncology experience to help the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), dba "Generex Oncology", further its synthetic cancer and influenza vaccine development efforts.  Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.

Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney.  He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA).  After his training he performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group.  In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.

In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the world wide lead for development of celecoxib in oncology to oversee the global research program.  Since that time he has had increasing responsibility for overseeing the global research plans and teams for irinotecan and dalteparin.  In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business.  Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications.  As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.

"We are very pleased to add Dr. Eagle to our team of scientific advisors," stated Anna Gluskin, the Company's President & Chief Executive Officer.  "His wealth of experience in oncology and drug development will be invaluable as we work to advance our vaccine technologies at Antigen Express.  Additionally, his hands-on experience in strategic alliances and partnerships will provide us with additional guidance as we seek to commercialize these platforms in the future."

Commenting on his decision to join the scientific advisory board of Generex, Dr. Eagle stated: "I am very excited to be a part of the important advancements in cancer vaccine technologies being made at Generex Oncology.  I look forward to advising the Company in its future oncology development efforts and helping Generex to navigate this important platform through its remaining trials and on to eventual commercialization."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation